Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
41%
Clinical Trial
39%
Gamma Urogastrone
32%
Epidermal Growth Factor Receptor 2
32%
Malignant Neoplasm
25%
Hormone Receptor
20%
Trastuzumab
20%
Diseases
19%
Recurrent Disease
16%
Neoadjuvant Chemotherapy
15%
Targeted Therapy
15%
Cervical Cancer
15%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
15%
Solid Malignant Neoplasm
14%
Metastatic Breast Cancer
13%
Cancer Therapy
13%
Neoadjuvant Therapy
12%
Biological Marker
12%
Palbociclib
12%
Radiation Therapy
11%
Metastatic Carcinoma
11%
Locally Advanced Breast Cancer
10%
Axilla
10%
Oncology
9%
Circulating Tumor DNA
9%
Neutropenia
9%
Paclitaxel
8%
Arm
8%
Biopsy Technique
8%
Trastuzumab Emtansine
8%
Phase II Trials
7%
Breast Tumor
7%
Overall Survival
7%
Heart Left Ventricle Ejection Fraction
7%
Capecitabine
7%
Adverse Event
7%
Triple Negative Breast Cancer
7%
Granulocyte Macrophage Colony Stimulating Factor
7%
Cell-Free DNA
7%
Circulating Tumor Cell
7%
Heart Function
7%
Tucatinib
7%
Progression Free Survival
7%
Mortality Rate
6%
Hazard Ratio
6%
Tumor
6%
Immunotherapy
5%
Adjuvant Therapy
5%
Fulvestrant
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
76%
Neoplasm
52%
Chemotherapy
43%
Gamma Urogastrone
33%
Epidermal Growth Factor Receptor 2
32%
Malignant Neoplasm
30%
Trastuzumab
29%
Clinical Trial
28%
Hormone Receptor
27%
Paclitaxel
24%
Diseases
20%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
18%
Metastatic Breast Cancer
16%
Solid Malignant Neoplasm
15%
Recurrent Disease
15%
Palbociclib
15%
Trastuzumab Emtansine
14%
Triple Negative Breast Cancer
14%
Biological Marker
12%
Uterine Cervix Cancer
11%
Adverse Event
11%
Overall Survival
11%
Tucatinib
10%
Progression Free Survival
10%
Immunotherapy
9%
Circulating Tumor DNA
9%
Fulvestrant
9%
Disease Free Survival
9%
Metastasis
9%
Phase II Trials
8%
Neutropenia
8%
Capecitabine
7%
Head and Neck Squamous Cell Carcinoma
7%
Crofelemer
7%
Cetuximab
7%
Granulocyte Macrophage Colony Stimulating Factor
7%
Diarrhea
7%
Recurrence Free Survival
6%
Phase I Trials
5%
Tolerability
5%
Lapatinib
5%
Cisplatin
5%
Doxorubicin
5%
Cyclin Dependent Kinase 4
5%
Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
38%
Trastuzumab
31%
Breast Cancer
29%
Hormone Receptor-positive
20%
Neoadjuvant Chemotherapy
18%
Metastatic Breast Cancer
17%
HER2-positive
16%
Tumor
16%
Paclitaxel
15%
Early Breast Cancer
15%
HER2-positive Breast Cancer
14%
Pathological Complete Response
14%
Palbociclib
12%
T-DM1
12%
Cyclin-dependent Kinase 4 (CDK4)
11%
Trastuzumab Emtansine
11%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
10%
Circulating Tumor Cells
10%
Tucatinib
10%
Clinical Trials
10%
Circulating Tumor DNA (ctDNA)
10%
HER2-targeted Therapy
10%
Phase I Trial
9%
Fulvestrant
9%
Chemotherapy
8%
Previously Treated
8%
Phase II Trial
8%
Complete Response Rate
8%
Cetuximab
8%
Basket Study
8%
Co-alterations
7%
Confidence Interval
7%
Adjuvant Trastuzumab
7%
Biomarkers of Response
7%
Phase II Study
7%
Platinum-based Chemotherapy
7%
Locally Advanced Breast Cancer
7%
Growth Factors
7%
Crofelemer
7%
Cell-free DNA Concentration
7%
Early-stage Cervical Cancer
7%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
HER2-negative Breast Cancer
7%
Multiple Assignment
7%
Advanced Solid Malignancies
7%
Axilla
7%
Breast Tumor
7%
Triple-negative Breast Cancer
7%
Solid Tumors
7%
Treatment-related Adverse Events
6%